» Articles » PMID: 15812263

Escitalopram and Suicidality in Adult Depression and Anxiety

Overview
Specialty Pharmacology
Date 2005 Apr 7
PMID 15812263
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The escitalopram clinical trial database, consisting of all placebo-controlled and relapse prevention trials within major depressive disorder (MDD) and anxiety disorders, was analysed for specific adverse events indicative of suicidal behaviour (fatal suicide, non-fatal self-harm or suicidal thoughts) in relation to treatment. The number of events was low, with no fatal suicides in the first 2 weeks of treatment. There was one fatal suicide during the full treatment period on placebo (incidence 0.1%; rate 0.003), and none on escitalopram. None of these figures were significantly different between escitalopram (n=2277) and placebo (n=1814) patients. There was no indication that escitalopram provokes suicidal behaviour compared to placebo in either MDD or anxiety disorders. Based on efficacy ratings (Montgomery-Asberg Depression Rating Scale, item 10), escitalopram was more efficacious versus placebo in lowering suicidal thoughts from weeks 1 through 8 in the treatment of patients with MDD.

Citing Articles

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Wang G, You X, Wang X, Xu X, Bai L, Xie J Neuropsychiatr Dis Treat. 2018; 14:2087-2097.

PMID: 30147321 PMC: 6097511. DOI: 10.2147/NDT.S164673.


Antidepressants and Suicide Risk: A Comprehensive Overview.

Pompili M, Serafini G, Innamorati M, Ambrosi E, Giordano G, Girardi P Pharmaceuticals (Basel). 2016; 3(9):2861-2883.

PMID: 27713380 PMC: 4034101. DOI: 10.3390/ph3092861.


Acute Treatment with a Novel TRPC4/C5 Channel Inhibitor Produces Antidepressant and Anxiolytic-Like Effects in Mice.

Yang L, Jiang F, Wu G, Deng K, Wen M, Zhou X PLoS One. 2015; 10(8):e0136255.

PMID: 26317356 PMC: 4552833. DOI: 10.1371/journal.pone.0136255.


Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Kirino E Patient Prefer Adherence. 2012; 6:853-61.

PMID: 23271894 PMC: 3526882. DOI: 10.2147/PPA.S22495.


Suicide and antidepressants: what current evidence indicates.

Nischal A, Tripathi A, Nischal A, Trivedi J Mens Sana Monogr. 2012; 10(1):33-44.

PMID: 22654381 PMC: 3353604. DOI: 10.4103/0973-1229.87287.